Category: Health Policy Analyses

The journals invite articles that discuss various aspects of health policy, in particular those concerned with pricing and reimbursement issues, the adoption of new health technologies, or policies to encourage ‘value-based’ decision-making. However, the journals’ scope does not include papers dealing with more general issues of health care financing, health insurance and cost-containment measures.

COST OF DIABETES MELLITUS – IS EARLY DIAGNOSIS A SAVIOR?

Accra, Ghana – The number of diabetes cases and the associated health care budget has been increasing worldwide. It has thus become a growing public health burden for patients, health care providers, and society. The cost of diabetes study has

Posted in Health Policy Analyses, ISPOR News & Press, Value in Health Regional Issues Tagged with: , , , , ,

DECONSTRUCTING PHARMACEUTICAL TENDERING: UNDERSTANDING THE UNDERLYING ELEMENTS

Latsia, Cyprus – Tendering is an aggressive pricing and reimbursement tool with proven potency in the pharmaceutical sector.  The pharmaceutical sector is exhibiting high annual sales-increase rates; therefore, the need for optimized, potent, and sustainable pricing and reimbursement tools is

Posted in Health Policy Analyses, ISPOR News & Press, Value in Health Regional Issues Tagged with: , , , , , ,

IS PAYERS’ DATABASE SUITABLE FOR CANCER SERVICE EVALUATION?

Budapest, Hungary – Malignant diseases represent a high burden for societies in Central and Eastern European countries. The data routinely collected in the database of the Hungarian National Health Insurance Fund can be used to assess some quality indicators related

Posted in Health Policy Analyses, ISPOR News & Press, Value in Health Regional Issues Tagged with: , ,

THE FOURTH HURDLE – CAN IT BE SIMPLIFIED?

Melbourne, Australia – While regulatory systems are well established within Asia-Pacific countries, formalised health technology assessment (HTA) based reimbursement systems are relatively new, yet rapidly evolving. Closer understanding of the different reimbursement processes within Asia-Pacific can allow for best-practice cross-pollination, leading

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

AUSTRALIA – CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA

London, UK – Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires

Posted in Health Policy Analyses Tagged with: , , ,

ENSURING THE FUTURE FOR CHINA’S ESSENTIAL DRUG POLICY

New Orleans, LA, USA & Shandong, China – China is one of the few middle-income countries with higher pharmaceutical cost out of total health care spending. The primary purpose of China’s National Essential Drug Policy (NEDP) in year 2009 was

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

HEALTH CARE DECISION MAKERS OPEN FOR PUBLIC AND PATIENT INVOLVEMENT IN COVERAGE DECISIONS

Brussels, Belgium – In a democratic system, politicians are elected to make decisions regarding health care priorities. In deliberation-driven systems, such as in Belgium, coverage decisions are based on the outcomes of a deliberation amongst stakeholders (including public authorities, providers,

Posted in Health Policy Analyses, Value in Health Tagged with: , , ,

IDENTIFYING THE FACTORS THAT ENHANCE POSITIVE DRUG REIMBURSEMENT RECOMMENDATION IN SCOTLAND

Rotterdam, The Netherlands – Given limited health care resources and rising expenditures on pharmaceuticals, policy makers are increasingly confronted with the challenging task to improve patient outcomes and reimburse new pharmaceutical interventions. Arguably, Scotland is often one of the first

Posted in Announcements, Health Policy Analyses, Value in Health Tagged with: , , , , , ,

NEW FRAMEWORK MEASURES FAIRNESS WHEN DISTRIBUTING VACCINES

Blacksburg, VA, USA – When vaccines are in short supply, public health officials must decide who among the public should be protected against disease – a decision that can hold moral and ethical implications. In order to avoid such concerns,

Posted in Announcements, Health Policy Analyses Tagged with: , , , , , ,